Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...
NEW HAVEN, Conn., June 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
I tested the Streamlights PROTAC HL® 4 HIGH LUMEN TACTICAL LIGHT, a dual power hand torch that throws can throw a beam out to 346 meters. The PROTAC HL® 4 is 8.63 inches long and weighs 1.1 lbs. It is ...
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that offer a promising therapeutic strategy against hard-to-treat diseases. Unlike traditional small molecule inhibitors, ...
Proteolytic targeting chimera (PROTAC) is a new type of drug design technology that works by inducing the degradation of target proteins. Unlike conventional small molecules that typically inhibit ...
A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...
New York, USA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight DelveInsight’s PROTAC Market Insights ...
Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...
– Preclinical data presented at the Biennial International LRRK2 Meeting highlighted the promise of PROTAC®-induced leucine-rich repeat kinase 2 (LRRK2) degradation as a potential treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback